Estrogen replacement therapy (ERT) for treatment of adolescent anorexia nervosa – An open label study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519908-27-01

Acronym

HNF1595-21

Enrollment

Registered

2025-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Brief summary

Anxiety levels measured by STAI-C and specific symptoms of anorexia measured by the EDE-Q

Detailed description

Cortisol, ghrelin, T3, T4 levels, weight gain, cognitive performance (WCST, CVLT II), and Beck Youth Inventory scores

Interventions

DRUGEstradot 50 mikrog/24 timer depotplaster

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Anxiety levels measured by STAI-C and specific symptoms of anorexia measured by the EDE-Q	—

Secondary

Measure	Time frame
Cortisol, ghrelin, T3, T4 levels, weight gain, cognitive performance (WCST, CVLT II), and Beck Youth Inventory scores	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026